Nobel Biocare releases interim financial report

Nobel Biocare has posted its latest interim financial results, which cover both the third quarter of 2009 and the first nine months of the year.

Its revenues were in-line with market conditions, the firm revealed, with growth easing by 6.8 per cent to 425.7 million euros (380.4 million pounds).

Net profit, excluding restructuring charges, stood at 87.8 million euros for the timeframe – a figure that has increased by 24 per cent compared to the same period of last year.

Additionally, operating cash flow reached 106.6 million euros, due to improved working capital management.

Chief executive officer of the firm Domenico Scala stated: “Our results demonstrate the strength of our business model even in today?s challenging market environment. During the past quarter, we concentrated on progressing our new NobelProcera offering.”

News of the firm’s financials comes after it announced the appointment of its new head of global operations Ernst Zangerle last month.